Kolexia
Escudier Bernard Cardiologie
Escudier Bernard
Cardiologie
Gustave-Roussy
Villejuif, France
719 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Néphrocarcinome Carcinomes Tumeurs du rein Métastase tumorale Tumeurs de la prostate Récidive tumorale locale Hypertension artérielle Tumeurs osseuses Tumeurs du cerveau

Collaborateurs

Voir plus
Albiges Laurence
Albiges Laurence
Gustave-Roussy, Villejuif, France
Negrier Marie-Sylvie
Negrier Marie-Sylvie
Centre Léon-Bérard, Lyon, France
Ravaud Alain
Ravaud Alain
Hôpital Saint-André, Bordeaux, France
Oudard Stephane
Oudard Stephane
Hôpital Européen Georges Pompidou, Paris, France

Industries

Voir plus
Ipsen
26 collaboration(s)
Dernière en 2023
BMS
10 collaboration(s)
Dernière en 2020
Eisai
4 collaboration(s)
Dernière en 2021
Novartis
1 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
The oncologist   06 mars 2024
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
European journal of cancer (Oxford, England : 1990)   03 février 2024
CheckMate 9ER: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Essai Clinique (BMS)   12 janvier 2024
23P Circulating immune cells and activity of immune checkpoint inhibitors in metastatic renal cell carcinoma
Abstract Book of the ESMO Immuno-Oncology Congress 2023 6-8 December 2023   01 décembre 2023
184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study
Abstract Book of the ESMO Immuno-Oncology Congress 2023 6-8 December 2023   01 décembre 2023
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214): A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Essai Clinique (BMS)   13 novembre 2023
Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma.
Journal for immunotherapy of cancer   09 novembre 2023
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
European urology oncology   07 octobre 2023
1909P Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
1906P Metastasized non-clear cell renal cell carcinoma: Which entities are dangerous? Results learned from reference pathology of the SuniForecast study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023